The information contained in this area of the website is for the purposes of AIM Rule 26.
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global lab network and product suite tailored for precision testing.
A full description of the business can be found here - Company Profile
To learn more about the Company, please watch the video of our recent 2022 Investor Roadshow
Board of Directors
The names of the directors and biographical details can be found here - Board of Directors
Information on Corporate Governance can be found here - Corporate Governance
UK Takeover Code Applicability
The Company is subject to the provisions of the UK City Code on Takeover and Mergers.
Country of Incorporation & Operations
The Company was incorporated and registered in Northern Ireland with registered number NI055207. Its main country of operation is Northern Ireland with wholly owned subsidiary undertakings in Northern Ireland, the Republic of Ireland, the US and Singapore.
Registered Office and principal trading address
Dataworks at Kings Hall Health & Wellbeing Park
Current Constitutional Documents
Details of Restrictions on the transfer of Securities
There are no restrictions on the transfer of the Company’s ordinary shares.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Details of any other exchanges or trading platform
The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.
AIM securities in issue: 84,472,431
The percentage of AIM securities not in public hands at 30 June 2023 was 38.63%.
The identity and shareholdings of the Company's significant shareholders can be found here - Significant Shareholders
The documents sent to shareholders can be found here.
To view the details of the Company’s Advisers please click here
To access notifications made by the Company please click here
This information was last updated on 30 June 2023.